CS

Chaitanya Sharad Ganapule

Active Director Managing Director DIN 06764001
DIN 06764001 First appointment Dec 2013 Primary industry Healthcare
Unlock full profile Investments · shareholding · contact details
Current companies 4 active board seats
Past companies 2 historical roles
Total affiliations 6 Since Dec 2013
Shareholding value •••• Premium profile

About Chaitanya Sharad Ganapule

Data last updated:

Chaitanya Sharad Ganapule is a Managing Director at Pearl Women's Hospital And Yash - Ivf India Private Limited (since 2014), Designated Partner at Satara Yash Ivf Llp (since 2019) and Designated Partner at Neowoman Healthcare Llp (since 2023), and holds 1 more current directorship. The companies operate in Healthcare and Pharma. The 2 current companies with reported revenue have a combined latest revenue of ₹10.34 Cr; the largest is Pearl Women's Hospital And Yash - Ivf India Private Limited at ₹9.46 Cr (FY 2025). Earlier, Chaitanya Sharad Ganapule was a Designated Partner at Be Well Pharmacy Llp (2022–2024) and Designated Partner at Vida Healthcare Llp (2018–2019).

DIN 06764001
Primary Designation Managing Director
Industry Healthcare
First Appointment 24 Dec 2013
Oldest Company Age 12 yrs
Largest company Pearl Women's Hospital And Yash - Ivf India Private Limited · ₹9.46 Cr (FY 2025)
Combined revenue ₹10.34 Cr across 2 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Managing Director19 Sep 20142014₹9.46 Cr (FY 2025)Active
Designated Partner12 Apr 20192019₹88 Lakh (FY 2023)Active
Designated Partner17 May 20232023Active
Designated Partner24 Dec 20132013Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Designated Partner05 Mar 20222019Active
Designated Partner18 Jun 20182018Active

Explore Director's current and past company associations Uncover their professional journey today!

Board colleagues of Chaitanya Sharad Ganapule

Directorship timeline

Open interactive timeline →
G-2 Sante Soin Llp
Satara Yash Ivf Llp
Pearl Women's Hospital And Yash - Ivf India Private Limited
Neowoman Healthcare Llp
Premium access

Shareholding and investment profile for Chaitanya Sharad Ganapule

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Chaitanya Sharad Ganapule

Chaitanya Sharad Ganapule currently holds 4 directorships: Pearl Women's Hospital And Yash - Ivf India Private Limited (Managing Director, since 19 Sep 2014, revenue ₹9.46 Cr (FY 2025)); Satara Yash Ivf Llp (Designated Partner, since 12 Apr 2019, revenue ₹88 Lakh (FY 2023)); Neowoman Healthcare Llp (Designated Partner, since 17 May 2023); G-2 Sante Soin Llp (Designated Partner, since 24 Dec 2013).

Chaitanya Sharad Ganapule was first appointed on 24 Dec 2013 as Designated Partner at G-2 Sante Soin Llp. The most recent appointment on record is 17 May 2023 at Neowoman Healthcare Llp.

The 2 current companies of Chaitanya Sharad Ganapule that report revenue have a combined latest revenue of ₹10.34 Cr: Pearl Women's Hospital And Yash - Ivf India Private Limited ₹9.46 Cr (FY 2025); Satara Yash Ivf Llp ₹88 Lakh (FY 2023).

Chaitanya Sharad Ganapule held 2 earlier board appointments: Be Well Pharmacy Llp (Designated Partner, 05 Mar 2022 to 27 Mar 2024); Vida Healthcare Llp (Designated Partner, 18 Jun 2018 to 07 May 2019).

The current boards of Chaitanya Sharad Ganapule's companies include Ravindra Dattatraya Kulkarni (Pearl Women's Hospital And Yash - Ivf India Private Limited), Subodh Annasaheb Howale (Satara Yash Ivf Llp), Padmaja Pranav Jadhav (Neowoman Healthcare Llp), Pramod Uttam Gaikwad (G-2 Sante Soin Llp).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available